Craft

BGI Genomics

Stock Price

¥46.4

2024-10-29

Market Capitalization

¥19.4 B

2024-10-28

Revenue

¥3.8 B

FY, 2024

BGI Genomics Summary

Company Summary

Overview
BGI Genomics (华大基因, 深圳华大基因股份有限公司) is a company offering genomic sequencing and proteomic services. It engages in DNA and RNA sequencing, hereditary cancer screening, non-invasive prenatal screening, etc. The company also provides mass spectrometry, pharma, and COVID-19 solutions. BGI Genomics caters to academic institutions, pharmaceutical companies, health care providers, and other organizations.
Type
Public
Status
Active
Founded
1999
HQ
Shenzhen, CN | view all locations
Website
https://www.bgi.com/global
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Zhao Lijian

    Zhao Lijian, Director, Chief Executive Officer

    • Wang Yujue

      Wang Yujue, Chief Financial Officer

      • Huo Shoujiang

        Huo Shoujiang, Chief Human Resource Officer

      • Du Yutao

        Du Yutao, Director, Deputy General Manager

        Operating MetricsView all

        Hospitals Served

        500

        FY, 2022

        Registered Users (Dr.Tom Data Mining System)

        8.5K

        H1, 2020

        Partners (Prenatal Diagnosis Centers)

        180
        5.3%

        FY, 2022

        LocationsView all

        10 locations detected

        • Shenzhen, Guang Dong Sheng HQ

          China

          Building 7, Huada Comprehensive Park, No. 21, Hong'an 3rd Street, Yantian District

        • Cambridge, MA

          United States

          One Broadway, 14th Floor

        • Brisbane, QLD

          Australia

          L6, CBCRC Building, QIMR, 300 Herston Rd

        • Copenhagen

          Denmark

          Ole Maaløes Vej 3

        • Addis Ababa, Addis Ababa

          Ethiopia

          Bole Lemi Industry Park Phase II

        • Hong Kong, New Territories

          Hong Kong

          16 Dai Fu Street, Tai Po Industrial Estate

        and 4 others

        BGI Genomics Financials

        Summary Financials

        Revenue (Q1, 2025)
        ¥669.2M
        Gross profit (Q1, 2025)
        ¥289.9M
        Net income (Q1, 2025)
        (¥55.3M)
        Cash (Q1, 2025)
        ¥3.9B
        EBIT (Q1, 2025)
        (¥100.2M)
        Enterprise value
        $16.6B

        Footer menu